Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) announced positive 4-6 week follow-up data from the first five lead-in patients in their ongoing proof-of-concept human clinical trial. The study evaluates the safety and effectiveness of their transvascular energy delivery system for ablating problematic nerves to reduce pain in pancreatic cancer patients. Dr. Robert Schwartz, Chief Medical Officer, discussed these results in a Virtual Investor 'What This Means' segment.

Positive

• Positive initial clinical data from first five lead-in patients
• Successfully progressing through proof-of-concept trial phase

Negative

• None.

Access the Virtual Investor “What This Means” Segment here

THE WOODLANDS, TX, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it recently participated in a Virtual Investor “What This Means” segment.

For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s recently announced 4-6 week positive follow-up data, from the first five “lead-in” patients in the Company’s ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain.

The “What This Means” segment can be accessed here.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com

FAQ

What are the results of Autonomix Medical's (AMIX) 4-6 week follow-up data in October 2024?

Autonomix Medical reported positive follow-up data from the first five lead-in patients in their proof-of-concept clinical trial for pancreatic cancer pain treatment.

What is the purpose of Autonomix Medical's (AMIX) current clinical trial?

The trial evaluates the safety and effectiveness of their transvascular energy delivery system for ablating problematic nerves to reduce pain in pancreatic cancer patients.

How many patients were included in AMIX's initial follow-up data analysis?

The follow-up data included the first five 'lead-in' patients from the ongoing proof-of-concept clinical trial.